Fortis Doctors Achieve Milestone by Curing Sickle Cell Disease via Bone Marrow Transplants

Sickle cell disease is a debilitating inherited blood disorder causing severe anemia, recurrent pain, organ damage, and reduced life expectancy, particularly affecting India and sub-Saharan Africa. The study underscored the importance of early diagnosis and timely transplantation, showing that performing the procedure before severe complications drastically improves survival. Fortis employed advanced protocols to reduce side effects and minimize graft-versus-host disease risk. Doctors noted many children previously dependent on transfusions are now healthy and active, highlighting the potential for curative treatment in resource-limited settings and heralding a new era for pediatric sickle cell disease care in India and beyond.

REFERENCE: Bhayana, S., Chakaroborty, S., Nathany, S., Danewa, A., Arora, S., Pal Singh, P., … Dua, V. (2025). Encouraging Outcomes of Hematopoeitic Stem Cell Transplantation in Pediatric Sickle Cell Disease- A Decade-Long Experience from the Developing World. Hemoglobin, 49(5), 317–322. https://doi.org/10.1080/03630269.2025.2568129